4-((2-(N-benzyl-1-methyl-1H-imidazole-4-sulfonamido)ethyl)((1-methyl-1H-imidazol-5-yl)methyl)amino)benzamide

ID: ALA1257301

Chembl Id: CHEMBL1257301

PubChem CID: 49781656

Max Phase: Preclinical

Molecular Formula: C25H29N7O3S

Molecular Weight: 507.62

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C(N)=O)cc2)Cc2ccccc2)c1

Standard InChI:  InChI=1S/C25H29N7O3S/c1-29-17-24(28-19-29)36(34,35)32(15-20-6-4-3-5-7-20)13-12-31(16-23-14-27-18-30(23)2)22-10-8-21(9-11-22)25(26)33/h3-11,14,17-19H,12-13,15-16H2,1-2H3,(H2,26,33)

Standard InChI Key:  AFBKWAHCXYIFKZ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA1257301

   4-[2-[Benzyl-(1-methylimidazol-4-yl)sulfonylamino]ethyl-[(3-methylimidazol-4-yl)methyl]amino]benzamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 507.62

Molecular Weight (Monoisotopic): 507.2053

AlogP: 2.15

#Rotatable Bonds: 11

Polar Surface Area: 119.35

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 6.22

CX LogP: 1.96

CX LogD: 1.94

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.33

Np Likeness Score: -1.21

References

1. Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD..  (2010)  Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.,  53  (19): [PMID:20822181] [10.1021/jm1001748]

Source

Source(1):

• Scientific Literature